carboplatin,durvalumab,paclitaxel,olaparib,bevacizumab
astrazeneca,merck,roche
['duo-o', 'gyn']
#asco23 gyn oral session!! very nice data of duo-o study in first line ovar an cancer.great discussion of prof fotopoulou! promising paper of io in front line. however, in my modest opinion a parpi arm in hrd patients is missing. will first study, engot-ov44 give us the clue? 